clinical trial · NCT05517447
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
Immunovant Sciences GmbH·phase3·terminated·n = 109
Thyroid Eye DiseaseObservational cohort studyBatoclimab
brief summary
This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.
started
Nov 6, 2022
primary completion
Apr 2, 2026
completion
Apr 2, 2026
last updated
Apr 29, 2026
official title
An Open-label Extension Study for Participants Who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol